Aspen Pharmacare wins Canada approval for generic Ozempic injection
Reuters··1 min read
FILE PHOTO: A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo
JOHANNESBURG, July 20 (Reuters) - South Africa's Aspen Pharmacare said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic semaglutide injectable used to treat adults with type 2 diabetes. Semaglutide is the active ingredient found in Novo Nordisk's blockbuster Ozempic diabetes treatment and Wegovy weight-loss medicine. (
JOHANNESBURG, July 20 (Reuters) - South Africa's Aspen Pharmacare said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic semaglutide injectable used to treat adults with type 2 diabetes.
Semaglutide is the active ingredient found in Novo Nordisk's blockbuster Ozempic diabetes treatment and Wegovy weight-loss medicine.
(Reporting by Nqobile Dludla;Editing by Alison Williams)